Saltar al contenido principal
amavitaRESEARCH

PARA PACIENTES - MIAMI

Tratamientos cardiacos del manana, sin costo, en Miami, hoy.

Siete estudios cardiovasculares activos. Coordinadores bilingues (EN-ES). Investigadores de clase mundial. Todas las visitas, medicamentos y procedimientos sin costo. Solicite en 60 segundos y le llamamos el mismo dia habil.

Devolucion misma dia / $0 costo / Bilingue EN-ES

Buscar mi estudio (60 segundos)Llamar (786) 703-5941

English

Sala de cateterismo de Advanced Cardiovascular of Miami
Centro Quirurgico Afiliado

Atencion cardiovascular avanzada en un entorno comodo y de un mismo dia

El unico centro ambulatorio de su tipo en el sur de la Florida.

Todos los procedimientos relacionados con el estudio se realizan en nuestro centro quirurgico afiliado de ultima generacion en Miami, para que reciba atencion cardiovascular avanzada en un entorno ambulatorio comodo y de un mismo dia.

9408 SW 87th Ave., Suite 303, Miami, FL 33176

Mostrando 7 de 7 estudios

Phase 1/2Insuficiencia CardiacaProximamente

VASA — Heart Failure with Preserved Ejection Fraction

Heart Failure with Preserved Ejection Fraction (HFpEF)

Protocolo: VS-041-102

A safety, tolerability, and biomarker trial of VS-041 in participants with Heart Failure with Preserved Ejection Fraction. Amavita Research Services is an enrolling site under Medpace clinical trial agreement, with Dr. Pedro Martinez-Clark as Principal Investigator.

Patrocinador: Vasa Therapeutics, Inc. · IP: Pedro Martinez-Clark, MD, FACC

Criterios de Elegibilidad

  • Adults with HFpEF (LVEF ≥ 50%)
  • Stable on guideline-directed medical therapy
  • Meeting protocol biomarker criteria
Solicitar este estudio
Phase 2Insuficiencia CardiacaProximamente

Pfizer C4921003 — PF-07328948 in HFpEF

Heart Failure with Preserved Ejection Fraction (HFpEF)

Protocolo: C4921003

Phase 2 study of PF-07328948, an oral branched-chain ketoacid dehydrogenase (BCKD) kinase inhibitor, in adults with heart failure. The trial evaluates the metabolic pathway that branched-chain amino acid catabolism plays in cardiac function in HFpEF.

Patrocinador: Pfizer · IP: Pedro Martinez-Clark, MD, FACC

Criterios de Elegibilidad

  • Adults with HFpEF (LVEF ≥ 50%)
  • On stable guideline-directed medical therapy
  • Meeting protocol metabolic / biomarker criteria
Solicitar este estudio
Phase 3Insuficiencia CardiacaProximamente

HERMES — Ziltivekimab in Heart Failure

Heart failure with mid-range or preserved ejection fraction and systemic inflammation

Protocolo: EX6018-4915

A Phase 3 randomized, placebo-controlled trial evaluating ziltivekimab, a fully human monoclonal antibody targeting interleukin-6, in patients with heart failure and systemic inflammation. Amavita Research Services is an enrolling site, with Dr. Pedro Martinez-Clark as Principal Investigator.

Patrocinador: Novo Nordisk · IP: Pedro Martinez-Clark, MD, FACC

Criterios de Elegibilidad

  • Adults with heart failure (HFmrEF or HFpEF)
  • Evidence of systemic inflammation (e.g., elevated hsCRP)
  • On stable guideline-directed medical therapy
Solicitar este estudio
Phase 2BInsuficiencia CardiacaProximamente

AnaCardio AC01 — Ghrelin Receptor Agonist in HFrEF

Heart Failure with Reduced Ejection Fraction (HFrEF)

Phase 2B study of AC01, an oral ghrelin receptor agonist, administered over 12 weeks in patients with chronic advanced heart failure with reduced ejection fraction (HFrEF). The trial is in site start-up.

Patrocinador: AnaCardio AB · IP: Pedro Martinez-Clark, MD, FACC

Criterios de Elegibilidad

  • Adults with chronic advanced HFrEF
  • On stable guideline-directed medical therapy
  • Meeting protocol functional and biomarker criteria
Solicitar este estudio
Phase 3Insuficiencia CardiacaProximamente

ICONIC-HF — Ferric Derisomaltose in Iron-Deficiency Heart Failure

Iron-Deficiency Chronic Heart Failure

Protocolo: P-Monofer-CHF-02

Phase 3 trial of ferric derisomaltose (intravenous iron) versus no intravenous iron in iron-deficient subjects with symptomatic chronic heart failure. ICONIC-HF measures the impact of IV iron supplementation on HF outcomes.

Patrocinador: Pharmacosmos · IP: Pedro Martinez-Clark, MD, FACC

Criterios de Elegibilidad

  • Adults with symptomatic chronic heart failure
  • Confirmed iron deficiency (TSAT <20% or ferritin criteria)
  • Stable on guideline-directed therapy
Solicitar este estudio
PivotalVascularProximamente

GREAT — Golazo® Peripheral Atherectomy System

Peripheral Artery Disease

Protocolo: AVA-CL-5000

The GREAT Trial evaluates the Golazo® Peripheral Atherectomy System for safe and effective atherectomy in patients with peripheral artery disease. Phase: device IDE study.

Patrocinador: Avantec Vascular · IP: Pedro Martinez-Clark, MD, FACC

Criterios de Elegibilidad

  • Adults 18+ with symptomatic PAD
  • Rutherford Class 2–4
  • Suitable target lesion on imaging
Solicitar este estudio
Phase 3HipertensionProximamente

ZENITH — Zilebesiran in Uncontrolled Hypertension

Hypertension with Cardiovascular Risk

Protocolo: ALN-AGT01-008

Phase 3 study of zilebesiran in patients with hypertension not adequately controlled and with either established cardiovascular disease or high risk for cardiovascular disease. Zilebesiran is a subcutaneous RNAi therapeutic targeting hepatic angiotensinogen.

Patrocinador: Alnylam Pharmaceuticals · IP: Dr. William W. O'Neill, MD, FACC

Criterios de Elegibilidad

  • Adults 18+ with uncontrolled hypertension
  • Established cardiovascular disease or high cardiovascular risk
  • On stable antihypertensive therapy
Solicitar este estudio

PREGUNTAS FRECUENTES

Preguntas frecuentes

Respuestas a las dudas mas comunes de pacientes que estan considerando participar en un estudio clinico en Amavita Research.